These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 11465300)

  • 1. Economic evaluation of a new acellular vaccine for pertussis in Canada.
    Iskedjian M; Einarson TR; O'Brien BJ; De Serres JG; Gold R; Gemmill IM; Milkovich N; Rosner A
    Pharmacoeconomics; 2001; 19(5 Pt 2):551-63. PubMed ID: 11465300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic impact of the introduction of an acellular pertussis vaccine in Canada: a 6-year analysis.
    Iskedjian M; De Serres G; Einarson TR; Walker JH
    Vaccine; 2010 Jan; 28(3):714-23. PubMed ID: 19895923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic evaluation of an extended acellular pertussis vaccine programme for adolescents in Ontario, Canada.
    Iskedjian M; Walker JH; Hemels ME
    Vaccine; 2004 Oct; 22(31-32):4215-27. PubMed ID: 15474711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic evaluation of pertussis prevention by whole-cell and acellular vaccine in Germany.
    Tormans G; Van Doorslaer E; van Damme P; Clara R; Schmitt HJ
    Eur J Pediatr; 1998 May; 157(5):395-401. PubMed ID: 9625337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The health and economic burden of pertussis in Canada: A microsimulation study.
    McGirr A; Fisman DN; Tuite AR
    Vaccine; 2019 Nov; 37(49):7240-7247. PubMed ID: 31585727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pertussis in adolescents and adults: should we vaccinate?
    Lee GM; Lebaron C; Murphy TV; Lett S; Schauer S; Lieu TA
    Pediatrics; 2005 Jun; 115(6):1675-84. PubMed ID: 15930232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic evaluation of an extended acellular pertussis vaccine program for adolescents in Québec, Canada.
    Iskedjian M; Walker JH; De Serres G; Einarson TR
    Paediatr Drugs; 2005; 7(2):123-36. PubMed ID: 15871632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidemiological and Economic Effects of Priming With the Whole-Cell Bordetella pertussis Vaccine.
    DeAngelis H; Scarpino SV; Fitzpatrick MC; Galvani AP; Althouse BM
    JAMA Pediatr; 2016 May; 170(5):459-65. PubMed ID: 27018830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pertussis immunization of adolescents in the United States: an economic evaluation.
    Caro JJ; Getsios D; El-Hadi W; Payne K; O'Brien JA
    Pediatr Infect Dis J; 2005 May; 24(5 Suppl):S75-82. PubMed ID: 15876932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An economic evaluation of universal pertussis vaccination in Italy.
    Beutels P; Bonanni P; Tormans G; Canale F; Crovari PC
    Vaccine; 1999 May; 17(19):2400-9. PubMed ID: 10392622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness analysis of a pertussis vaccination programme for Japan considering intergenerational infection.
    Itatani T; Shimizu S; Iwasa M; Ohkusa Y; Hayakawa K
    Vaccine; 2013 Jun; 31(27):2891-7. PubMed ID: 23570987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of adult pertussis vaccination in Germany.
    Lee GM; Riffelmann M; Wirsing von Konig CH
    Vaccine; 2008 Jul; 26(29-30):3673-9. PubMed ID: 18538901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pertussis vaccination strategies for neonates--an exploratory cost-effectiveness analysis.
    Scuffham PA; McIntyre PB
    Vaccine; 2004 Jul; 22(21-22):2953-64. PubMed ID: 15246632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Whole-cell and acellular pertussis vaccination programs and rates of pertussis among infants and young children.
    Vickers D; Ross AG; Mainar-Jaime RC; Neudorf C; Shah S
    CMAJ; 2006 Nov; 175(10):1213-7. PubMed ID: 17098950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pertussis and pertussis vaccine: further analysis of benefits, risks and costs.
    Hinman AR; Koplan JP
    Dev Biol Stand; 1985; 61():429-37. PubMed ID: 3938968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic evaluation of the 7-vaccine routine childhood immunization schedule in the United States, 2001.
    Zhou F; Santoli J; Messonnier ML; Yusuf HR; Shefer A; Chu SY; Rodewald L; Harpaz R
    Arch Pediatr Adolesc Med; 2005 Dec; 159(12):1136-44. PubMed ID: 16330737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of strategies for use of acellular pertussis vaccine in adolescents and adults: a cost-benefit analysis.
    Purdy KW; Hay JW; Botteman MF; Ward JI
    Clin Infect Dis; 2004 Jul; 39(1):20-8. PubMed ID: 15206048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of models to identify cost-effective interventions: pertussis vaccination for pediatric health care workers.
    Greer AL; Fisman DN
    Pediatrics; 2011 Sep; 128(3):e591-9. PubMed ID: 21844056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cost of epidemiological transition: a study of a decrease in pertussis vaccination coverage.
    Girard DZ
    Health Policy; 2005 Nov; 74(3):287-303. PubMed ID: 15951048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness analysis of universal maternal immunization with tetanus-diphtheria-acellular pertussis (Tdap) vaccine in Brazil.
    Sartori AMC; de Soárez PC; Fernandes EG; Gryninger LCF; Viscondi JYK; Novaes HMD
    Vaccine; 2016 Mar; 34(13):1531-1539. PubMed ID: 26899375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.